The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

With the recent report of increase in stroke cases observed after this holiday season by the Department of Health (DOH)1, ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...